Sivik Global Healthcare LLC Purchases 20,000 Shares of Smith & Nephew SNATS, Inc. $SNN

Sivik Global Healthcare LLC grew its holdings in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 16.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 140,000 shares of the medical equipment provider’s stock after purchasing an additional 20,000 shares during the quarter. Smith & Nephew SNATS comprises approximately 1.2% of Sivik Global Healthcare LLC’s portfolio, making the stock its 26th biggest holding. Sivik Global Healthcare LLC’s holdings in Smith & Nephew SNATS were worth $4,288,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Hexagon Capital Partners LLC boosted its holdings in Smith & Nephew SNATS by 63.3% in the 1st quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 406 shares during the period. Richards Merrill & Peterson Inc. boosted its holdings in shares of Smith & Nephew SNATS by 500.0% in the first quarter. Richards Merrill & Peterson Inc. now owns 1,200 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 1,000 shares during the period. Bessemer Group Inc. boosted its holdings in shares of Smith & Nephew SNATS by 3,471.4% in the first quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider’s stock worth $49,000 after acquiring an additional 1,701 shares during the period. Banque Transatlantique SA purchased a new position in shares of Smith & Nephew SNATS in the first quarter valued at $52,000. Finally, Opal Wealth Advisors LLC bought a new stake in shares of Smith & Nephew SNATS during the 1st quarter valued at $73,000. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Stock Performance

NYSE:SNN opened at $35.09 on Friday. The stock has a market cap of $14.97 billion, a P/E ratio of 16.24, a PEG ratio of 0.97 and a beta of 0.69. The company has a quick ratio of 1.40, a current ratio of 3.00 and a debt-to-equity ratio of 0.60. The business’s 50-day moving average price is $36.63 and its two-hundred day moving average price is $31.47. Smith & Nephew SNATS, Inc. has a twelve month low of $23.69 and a twelve month high of $38.79.

Smith & Nephew SNATS Cuts Dividend

The business also recently announced a semi-annual dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 3rd will be given a dividend of $0.285 per share. The ex-dividend date is Friday, October 3rd. This represents a yield of 165.0%. Smith & Nephew SNATS’s payout ratio is presently 26.39%.

Analyst Upgrades and Downgrades

Several brokerages have commented on SNN. Weiss Ratings restated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday. Wall Street Zen lowered shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research report on Friday, October 3rd. Finally, Canaccord Genuity Group boosted their price objective on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the company a “hold” rating in a research note on Monday, August 18th. Seven equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $36.00.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.